The STRAW+10 Staging System: Where Are You in the Menopause Transition?

Why Staging Matters

One of the most disorienting aspects of the menopause transition is not knowing where you are in it. Symptoms can appear, disappear, and shift over months or years. Cycles become unpredictable. You may feel like you are in a kind of hormonal limbo — not clearly "before" menopause, not clearly "after" it.

This ambiguity is not just frustrating for women experiencing it. It has historically been a problem for researchers and clinicians as well. For decades, the language around the menopause transition was imprecise. Terms like "premenopause," "perimenopause," and "climacteric" were used inconsistently, making it difficult to compare research findings or provide clear clinical guidance.

In 2001, the Stages of Reproductive Aging Workshop (STRAW) convened to solve this problem. The result was a standardized staging system for female reproductive aging — updated in 2011 as STRAW+10 — that provides a common framework for classifying where a woman is in the transition from reproductive life through postmenopause.

The Architecture of STRAW+10

STRAW+10 divides a woman's reproductive lifespan into seven stages, numbered relative to the final menstrual period (FMP), which is designated as stage 0. Stages before the FMP carry negative numbers; stages after carry positive numbers.

The system uses three primary criteria to define each stage: menstrual cycle characteristics, endocrine biomarkers (primarily FSH and AMH), and descriptive features like symptoms. Menstrual cycle changes remain the most accessible and clinically useful criteria for most women and providers.

Reproductive Stages (Stages -5 to -3)

These are the years of normal reproductive function. STRAW+10 divides them into early, peak, and late reproductive stages.

• Stage -5 (Early Reproductive): Menstrual cycles may still be variable as the hypothalamic-pituitary-ovarian axis matures. This is the period shortly after menarche when cycles are becoming established.
• Stage -4 (Peak Reproductive): Cycles are regular and predictable. Fertility is at its highest. FSH and AMH levels are normal.
• Stage -3 (Late Reproductive): Cycles remain regular, but subtle changes begin. AMH and antral follicle count start to decline. FSH may begin to rise slightly, though it often remains within the normal range. This stage is further divided into -3b (subtle changes in cycle length, typically shorter) and -3a (more noticeable changes in FSH, with cycles still regular but potentially shorter).

The late reproductive stage is clinically significant because it is when fertility begins to decline meaningfully, even though a woman may feel perfectly normal. For women considering future pregnancy, the transition from -3b to -3a is an important inflection point.

The Menopausal Transition (Stages -2 and -1)

This is what most people mean when they say "perimenopause." STRAW+10 divides it into two stages:

• Stage -2 (Early Menopausal Transition): The defining feature is increased variability in menstrual cycle length — a persistent difference of 7 or more days in consecutive cycle lengths. "Persistent" means this pattern is observed in at least 10 consecutive cycles. FSH levels are elevated but variable.
• Stage -1 (Late Menopausal Transition): Characterized by skipped cycles — specifically, an interval of 60 or more days between periods. Amenorrhea (absence of periods) of increasing duration occurs. FSH levels are frequently elevated above 25 IU/L. Vasomotor symptoms often begin or intensify during this stage.

The distinction between early and late menopausal transition is clinically useful. Women in stage -2 often present with symptoms that are confusing — their cycles are "off" but still coming, and they may not connect their symptoms to hormonal changes. By stage -1, the pattern is usually more recognizable, with obvious skipped periods and often more pronounced symptoms.

The Final Menstrual Period (Stage 0)

Menopause itself is defined retrospectively: it is the point at which a woman has gone 12 consecutive months without a menstrual period, assuming no other medical cause (such as pregnancy, certain medications, or hypothalamic amenorrhea). The FMP can only be identified in hindsight — you cannot know it is your last period until a full year has passed.

This retrospective definition is a significant source of uncertainty. During late perimenopause, a woman may go 3 or 4 months without a period, assume she is approaching menopause, and then have another period. This stop-start pattern can repeat for months or years.

Postmenopause (Stages +1 and +2)

• Stage +1a (Early Postmenopause): The first two years after the FMP. FSH continues to rise, and estradiol levels fall to consistently low levels. Vasomotor symptoms are typically most frequent and severe during this period.
• Stage +1b (Early Postmenopause): Years 2 through approximately 6 after the FMP. FSH stabilizes at elevated levels. Symptoms may begin to moderate, though many women continue to experience vasomotor symptoms during this period.
• Stage +1c (Early Postmenopause): Approximately years 3 to 6 after the FMP, representing the period during which symptom stabilization continues.
• Stage +2 (Late Postmenopause): Extends from approximately 6 years post-FMP through the end of life. Hormonal levels are stable. Ongoing health concerns shift toward the long-term consequences of estrogen deficiency: bone loss, cardiovascular risk, and genitourinary symptoms.

The Biomarker Picture

STRAW+10 incorporates endocrine biomarkers, but with important caveats about their limitations during the transition.

FSH (Follicle-Stimulating Hormone)

FSH is the most commonly measured hormone in the context of perimenopause. It rises as ovarian function declines because the pituitary is working harder to stimulate follicle development. However, during the menopausal transition, FSH levels can fluctuate dramatically — a single measurement may be in the "normal" range one month and elevated the next.

The STRAW+10 system notes that FSH is most useful in late perimenopause and postmenopause, where it is consistently elevated (typically above 25-30 IU/L). In early perimenopause, FSH is an unreliable indicator. This is a critical point that is often missed: a "normal" FSH does not rule out perimenopause.

AMH (Anti-Mullerian Hormone)

AMH is produced by small antral follicles in the ovaries and provides a relatively stable measure of ovarian reserve. Unlike FSH, AMH does not fluctuate significantly across the menstrual cycle, making it a more reliable snapshot. AMH declines progressively throughout the reproductive lifespan and becomes undetectable around the time of menopause.

The 2011 STRAW+10 update incorporated AMH as a supportive criterion, recognizing its potential utility in staging. However, standardized reference ranges for staging purposes are still evolving, and AMH is not yet universally used in clinical practice for this purpose.

Estradiol

Counterintuitively, estradiol levels are often elevated — sometimes dramatically — during early perimenopause, as the pituitary drives FSH higher and stimulates remaining follicles more aggressively. This means that measuring estradiol during perimenopause can be misleading: a high level does not indicate normal reproductive function, and it does not rule out the menopausal transition.

Limitations of the System

STRAW+10 was designed primarily for research standardization, and while it is invaluable for that purpose, it has practical limitations in the clinic.

• Menstrual cycle data is foundational, but not always available. Women using hormonal contraception, those who have had a hysterectomy (but retain their ovaries), and those with certain menstrual disorders cannot be staged using cycle criteria alone. STRAW+10 acknowledges this and suggests relying more heavily on biomarkers in these populations.
• Individual variation is enormous. Two women at the same STRAW+10 stage can have dramatically different symptom profiles. The staging system describes population-level patterns, not individual experiences.
• The stages are not rigid timelines. Progression through the stages is not linear or predictable. A woman may remain in one stage for years or move through it quickly.
• Biomarker cutoffs are not absolute. There is no single FSH or AMH value that definitively places a woman in a specific stage. The system uses ranges and patterns, which require longitudinal data — multiple measurements over time — to interpret meaningfully.

Why This Framework Matters for You

Despite its limitations, STRAW+10 provides something genuinely valuable: a shared language and a map. When you understand the stages, you can begin to place your own experience in context. The erratic cycles of early perimenopause look different from the skipped periods of late perimenopause, which look different from the stable (but low) hormonal landscape of postmenopause. Knowing where you likely are helps set expectations, guide treatment decisions, and reduce the anxiety that comes from not knowing what is happening.

For healthcare providers, STRAW+10 offers a structured way to communicate about reproductive aging that goes beyond "your labs look fine" or "you might be starting menopause." It encourages a longitudinal perspective — looking at patterns over time rather than isolated snapshots.

Practical Application: Identifying Your Stage

While a definitive staging determination should involve a healthcare provider, you can begin to orient yourself using the following questions:

1. Are your cycles still regular? If yes, you are likely still in the reproductive stages, though subtle changes (slightly shorter cycles, earlier periods) may indicate late reproductive (stage -3).
2. Have your cycle lengths started to vary by more than 7 days? If this pattern is consistent, you may be in early menopausal transition (stage -2).
3. Have you skipped a period entirely — 60 or more days between cycles? This is the hallmark of late menopausal transition (stage -1).
4. Has it been 12 or more months since your last period? If so, and there is no other explanation, you have reached menopause and are now in postmenopause.

The value of tracking your cycles — not just "when" but also flow characteristics, cycle length, and associated symptoms — becomes clear in this context. Longitudinal data makes it possible to identify patterns that a single office visit cannot capture.

From Framework to Personalized Understanding

STRAW+10 is a population-level tool, and your experience will be individual. Some women move through the transition in 2 to 3 years; others take a decade. Some have severe symptoms; others notice very little. Ethnicity, genetics, body composition, lifestyle, and prior health history all influence how the transition unfolds.

The staging system does not predict your individual trajectory. What it does is provide a framework for understanding that the transition follows recognizable patterns, that what you are experiencing is biologically grounded, and that there are evidence-based approaches for management at every stage. That clarity, in a process often defined by confusion, is a meaningful starting point.